June 07th, 2022
CYTENA enters long term OEM supply agreement with PAIA and launches the F.QUANT Titer, high-throughput titer quantification assays for antibodies and Fc fusion proteins
The F.QUANT Titer assays enable cost-effective identification of high-producer clones for biopharmaceutical cell line development utilizing fluorescence plate readers
Today CYTENA, a BICO group company (Nasdaq Stockholm: BICO) and a leading provider of high-precision instruments for handling biological cells and PAIA Biotech GmbH, a developer of assays for the rapid analysis of antibodies and proteins based on its proprietary assay technology, announced they have signed a long-term OEM agreement. Under the terms of this agreement, CYTENA launched the F.QUANT Titer, a plate-based high-throughput titer quantification assay for antibodies, bispecifics or Fc fusion proteins based of PAIA’s patented technology. The F.QUANT Titer expands CYTENA’s cell line development portfolio enabling fast and cost-effective plate-based assays for high-throughput analysis of culture samples for titers with a very small sample volume.
The new F.QUANT Titer provides biopharma professionals an easy-to-use and cost-effective solution for the identification of high-producer clones based on fluorescence intensity without a need for capital investment for a dedicated instrument. The F.QUANT Titer assays further strengthens CYTENA’s cell line development product portfolio and contributes to bring affordable solutions for faster drug development to life science industry as a BICO group company.
Sebastian Giehring, CEO of PAIA Biotech, comments: “We are excited to partner with CYTENA, which share our goals of providing integrated solutions for cell line development and upstream development. With this partnership, we will be able to accelerate our growth, develop novel assays and make our unique assay technology available to more customers around the world.”
“We are thrilled to be bringing the F.QUANT Titer to the cell line development market. CYTENA has been developing cutting edge single-cell dispensers and have utilized this expertise to develop a fully-automated cell line development platform, the C.STATION, which enables accessibility to all from single-cell cloning of transfected cells to selecting high-producing clones to upscaling. The F.QUANT Titer complements this workflow for mAb titer monitoring for high-producer identification. We look forward to enabling the biopharma industry with this technology which will streamline the development of biotherapeutics.” Julian Riba, CEO, CYTENA.
PAIA Biotech, founded 2014 in Cologne/Germany, uses its patented microplate detection technology for developing high throughput bead-based assays. The assays focus on the quantification of biotherapeutics and on screening for critical quality attributes like glycosylation and aggregation. PAIA´s assay technology allows researchers to miniaturize and automate workflows in cell line and upstream development and helps to de-risk cell line selection and the optimization of process conditions by addressing quality related parameters early in the process. In addition to off-the-shelf assay products, PAIA Biotech offers the world´s first glycan screening assay service with fast turnaround that meet the requirements of cell line development labs.
CYTENA is a leading provider of high-precision instruments for isolating, dispensing, imaging, analyzing and handling biological cells. The company continues to build on the success of the single-cell dispensing technology it patented as a spin-off from the University of Freiburg, Germany, in 2014. Today, as part of BICO, the world’s leading bio convergence company, CYTENA’s award-winning devices are still manufactured in Germany and used at prestigious academic and pharmaceutical labs around the world to automate workflows in numerous application areas, including stable cell line development, single-cell omics, high-throughput screening and drug discovery. CYTENA’s breakthrough innovations for the lab combine advanced automation, state-of-the-art software engineering and the latest insights in cell biology to maximize efficiencies in the life sciences and create the future of health. Learn more at www.cytena.com.
Founded in 2016, BICO (formerly CELLINK) is the leading bio convergence company in the world. By combining different technologies, such as robotics, artificial intelligence, computer science, and 3D bioprinting with biology, we enable our customers to improve people's health and lives for the better.
The company has a focus on developing technologies that will advance Health 4.0 Next Generation Core Industry Ecosystems that enable tissue engineering, diagnostics, multiomics, and cell line development. BICO’s technologies enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. We create the future of health.
The Group’s instruments in the field amounts to 25,000, including all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 9,500 publications. BICO is listed on Nasdaq Stockholm under BICO. www.bico.com
Cologne, September 1st, 2020
PAIA introduces its new Glycan Screening Services business
PAIA Biotech officially launches its new Glycan Screening Services business starting from September 2020.
This new offering is the first glycan screening service which is truly adapted to the needs of customers in the CLD and Upstream development departments.
It allows our customers to screen up to hundreds of supernatant samples in less than two weeks and obtain product quality related data at an early stage.
“With this new service we provide our customers with an easy access to our glycan screening technology and our experienced team here at PAIA Biotech” says PAIA´s CEO Sebastian Giehring,“ we have seen growing interest in these kinds of services in the past year and are happy to making this an official product now.”
PAIA´s glycan screening services are based on the patented PAIA technology and follow standardized workflows that utilize PAIA´s glycan screening assays. These customizable assay kits continue to be marketed as consumables by PAIA Biotech.
Cologne, July 1st, 2020
PAIA receives Eurostars grant for TIPQmed project
PAIA Biotech is pleased to announce that the project “Targeted Improvement of Therapeutic Protein Quality Through Cell Culture Media” (TIPQMed) project was granted a total of about € 1,8 Mio. Euro through the Eurostars program over the next 30 months.
The goal is to identify cell culture media compositions that allow precise modulation of product quality attributes and use high throughout technologies to systematically test a multitude of conditions. The international TIPQMed consortium is led by Florabio Teknololoji (Turkey) and comprises technology providers PAIA Biotech (Germany), GlycoMScan (Netherlands) and Biberach University of Applied Sciences (Germany).
"The influence of culture media on protein glycosylation has been a mystery over decades.We will finally go into the absolute details to understand the dependencies and develop novel culture media", says Aziz Cayli, CEO of Florabio. “We believe that TIPQMed has a good chance for success because of the complementing expertise and willingness to succeed for all of the project members."
PAIA´s CEO Sebastian Giehring commented: ”We are excited to demonstrate our ability to screen product quality in cell line and bioprocess development in such a comprehensive project and refine our assay technology together with our partners."
Monique Scherpenzeel, CEO of GlycoMScan added:“We are very happy to have here the right capabilities and collaborations to precisely monitor the influence of cell culture conditions on therapeutic antibody glycosylation, which is the fulfillment of my long-standing wish to contribute to optimal treatment efficacy through understanding the process of glycosylation.”
For Hans Kiefer, one of the collaborators at Biberach University of Applied Sciences, this project "is an excellent opportunity to use and extend our capabilities in automated protein analysis and chemometric modelling in a real-life setting, where the path to market is short."
Eurostars supports international innovative projects led by research and development- performing small- and medium-sized enterprises (R&D-performing SMEs). With its bottom-up approach, Eurostars supports the development of rapidly marketable innovative products, processes and services that help improve the daily lives of people around the world. Eurostars is a joint program between EUREKA and the European Commission, co-funded from the national budgets of 36 Eurostars Participating States and Partner Countries and by the European Union through Horizon 2020.